# Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

> **NCT02554396** · PHASE2 · COMPLETED · sponsor: **LENZ Therapeutics, Inc** · enrollment: 20 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** PRX-100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02554396
- **Lead sponsor:** LENZ Therapeutics, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02554396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02554396, "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02554396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*